GSDME and prostate cancer: During this process, the generated ROS activated Caspase‐3/gasdermin E (GSDME)‐dependent pyroptosis in RM‐1 prostate cancer cells, leading to the release of abundant DAMPs and pro‐inflammatory cytokines.